NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure (NGAL-CKF)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2013 by Hopital Jean Minjoz.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Prof. Sidney Chocron, Hopital Jean Minjoz Identifier:
First received: October 22, 2010
Last updated: March 1, 2013
Last verified: March 2013

Primary endpoint: To evaluate predictive value of plasmatic levels of Neutrophil Gelatinase Associated Lipocalin (NGAL) to reveal acute kidney failure after cardiac surgery in patients with preoperative chronic kidney failure Secondary endpoint is to obtain threshold values of NGAL.

Cardiac Surgical Procedures

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Plasmatic Level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Marker of Acute Kidney Failure in Patients With Preoperative Chronic Kidney Failure Undergoing Cardiac Surgery.

Resource links provided by NLM:

Further study details as provided by Hopital Jean Minjoz:

Primary Outcome Measures:
  • Neutrophil Gelatinase Associated Lipocalin (NGAL) level [ Time Frame: From surgery to discharge from hospital ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Blood samples

Estimated Enrollment: 100
Study Start Date: August 2010
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Detailed Description:



Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with a chronic kidney failure, undergoing cardiac surgery.


Inclusion Criteria:

  • Renal clearance less than 60 mL/min
  • Able to give written consent
  • Elective valve surgery
  • Elective CABG surgery

Exclusion Criteria:

  • Less than 18 years old
  • Iodine injection within 3 days before surgery
  • Iodine injection within 24 first postoperative hours
  • preoperative infection
  • evolutive cancer disease
  • Refusal
  • Pregnancy
  • Unable to give written consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01227122

Centre hospitalier Universitaire (CHU) Jean Minjoz Recruiting
Besançon, Franche-Comté, France, 25000
Contact: CHOCRON Sidney, MD, PhD    +33381668662   
Principal Investigator: Chocron Sidney, MD, PhD         
Sub-Investigator: Andrea Perrotti, MD         
Sub-Investigator: Siamak Davani, MD, PhD         
Sub-Investigator: Camille Durst, MD         
Sponsors and Collaborators
Hopital Jean Minjoz
Principal Investigator: Chocron Sidney, MD, PhD Centre Hospitalier Universitaire (CHU) Jean Minjoz, Besançon, France
  More Information

Additional Information:
No publications provided

Responsible Party: Prof. Sidney Chocron, MD, PhD, Hopital Jean Minjoz Identifier: NCT01227122     History of Changes
Other Study ID Numbers: 2010-A00111-38
Study First Received: October 22, 2010
Last Updated: March 1, 2013
Health Authority: France: Agence Française Sécurité Sanitaire des Produits de Santé (AFSSAPS)

Keywords provided by Hopital Jean Minjoz:
NGAL plasmatic level
Cardiac Surgery Procedures

Additional relevant MeSH terms:
Acute Kidney Injury
Kidney Failure, Chronic
Renal Insufficiency
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases processed this record on October 13, 2015